Pliant Therapeutics, Inc.
700 Saginaw Drive
About Pliant Therapeutics, Inc.
Pliant Therapeutics is focused on discovering, developing and commercializing breakthrough treatments for fibrotic diseases.
By harnessing the therapeutic potential of integrin biology and TGF-ß modulation, Pliant aims to prevent or even reverse fibrosis to address the needs of many patients. The company also aims to build a patient registry for certain areas of fibrotic disease to both increase understanding of natural disease progression, and fuel biomarker discovery.
Pliant’s co-founders include world-renowned researchers from University of California, San Francisco (UCSF), who bring broad experience in fibrosis biology and small molecule chemistry. Together, the Pliant team is dedicated to translating scientific advances in fibrosis biology into novel therapies for patients in need.
Founders: Dean Sheppard, Bill DeGrado, Hal Chapman and Bradley Backes
CEO: Bernard Coulie
CBO: Hans Hull
CTO: Craig Muir
Please click here for Pliant job opportunities.
Please click here for clinical trial information.
24 articles with Pliant Therapeutics, Inc.
Pliant Therapeutics Announces Strategic Collaboration to Develop Novel Therapies for NASH and Fibrotic Diseases
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced it has entered into a strategic collaboration and license agreement with Novartis covering the development and commercialization of Pliant's preclinical product candidate, PLN-1474 and up to three additional integrin targets.
Pliant Therapeutics Announces Publication Demonstrating Feasibility of Positron Emission Tomography (PET) Tracers for Imaging Fibrosis in Patients with Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of fibrosis, announced the publication of a study evaluating the use of a positron emission tomography (PET) tracer for the detection of idiopathic pulmonary fibrosis (IPF) through the recognition of protein integrin avb6.
Pliant Therapeutics Reports Positive Results of Phase 1b Clinical Study Supporting Advancement of PLN-74809 for Treatment of Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc. announced the successful completion of a Phase 1b clinical trial of its lead product candidate, PLN-74809, an oral small-molecule dual selective inhibitor of αvß6 and αvß1 integrins that is being developed for the treatment of idiopathic pulmonary fibrosis, and primary sclerosing cholangitis.
Pliant Therapeutics Reports Positive Results of Phase 1 Clinical Study Support Advancement of PLN-74809 for Idiopathic Pulmonary Fibrosis
Preclinical Studies Demonstrating Anti-fibrotic Effect of Integrin Inhibitor to be Presented at American Thoracic Society International Conference
Pliant Therapeutics Presents Data in Human NASH Liver Tissue at The International Liver Congress 2019 Hosted by the European Association for the Study of the Liver (EASL)
Pliant Therapeutics, Inc. announced the presentation of in vivo data highlighting product candidate PLN-1474 for fibrotic liver diseases in an oral presentation at The International Liver Congress™ 2019 hosted by the European Association for the Study of the Liver.
Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced the appointment of Smital Shah to its board of directors as an independent director.
Pliant Therapeutics, Inc. announced that Bernard Coulie, M.D., Ph.D., president and chief executive officer, will present an update on the company and its programs at two upcoming healthcare investor conferences.
1/4/2019Biopharma companies begin 2019 with a flurry of hiring to fill executive leadership spots, including Dermavant, UroGen, Melinta, Translate Bio, and more.
Pliant Therapeutics Appoints Keith Cummings as Chief Financial Officer and Eduard Gorina as Vice President, Clinical Development
Pliant Therapeutics, Inc., a biotechnology company unraveling and targeting the key biological pathways driving fibrosis, today announced that Keith Cummings, M.D., MBA, has joined the company as chief financial officer and Eduard Gorina, M.D., has joined as vice president, clinical development.
Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that it has dosed the first cohort of subjects in a Phase 1 clinical study evaluating the safety, tolerability, pharmacodynamics and pharmacokinetics of anti-fibrotic agent PLN-74809.
Pliant Therapeutics, Inc. today announced that Bernard Coulie, M.D., Ph.D., president and chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare Conference. Dr. Coulie's presentation will take place at 9:00 a.m. PST on Wednesday, January 9, 2019, at the Westin St. Francis in San Francisco, Calif.
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis
Dr. Bertus Eksteen Joins Scientific Advisory Board
Pliant Therapeutics, Inc, today announced company scientists and research collaborators will present in vivo data highlighting Pliant's clinical product candidates in two posters at The Liver Meeting® 2018
Pliant Therapeutics Announces Research Collaboration with Cleveland Clinic to Develop New Disease Targets for Gastrointestinal Fibrosis
Pliant Therapeutics, Inc. today announced that they have entered into a multi-year joint research collaboration with Cleveland Clinic to accelerate the discovery of potential disease targets for gastrointestinal fibrosis.
Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Idiopathic Pulmonary Fibrosis
Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company's anti-fibrotic lead compound, PLN-74809, for the treatment of idiopathic pulmonary fibrosis (IPF).
Pliant Therapeutics Raises $62 Million in Series B Financing to Advance Therapies for Fibrotic Diseases
Pliant Therapeutics, Inc. announced that it has raised $62 million in a Series B financing.
7/16/2018Two months after unveiling a new approach to identify novel biomarkers for the detection and treatment of idiopathic pulmonary fibrosis, South San Francisco-based Pliant Therapeutics secured $62 million in a Series B financing round to support its research programs.
Pliant Therapeutics Presents Idiopathic Pulmonary Fibrosis Biomarker Discovery Research at American Thoracic Society 2018 International Conference
Pliant Therapeutics, Inc. today presents at the American Thoracic Society 2018 International Conference a new approach to identify novel biomarkers to improve diagnosis, selection and assessment of treatments for Idiopathic Pulmonary Fibrosis (IPF)
Pliant Appoints Katerina Leftheris, Ph.D., As Vice President Of Chemistry And John Curnutte, M.D., Ph.D. To The Board Of Directors